CD38 and Miyoshi myopathy: Similarly, DNMTis have been shown to upregulate CD38 expression on multiple myeloma (MM) plasma cells, enhancing the anti-MM efficacy of daratumumab via increased antibody-dependent cellular cytotoxicity [201].